Table 1.

Main and stratified associations for DLBCL risk by autoimmune condition and DLBCL PRS in participating InterLymph Consortium studies.

Autoimmune conditions	DLBCL PRS	Controls	DLBCL	OR (95% CI)	P interaction a
None		5,064	1,808	1.00 (Ref)
Any		193	106	1.42 (1.10–1.83)	–
No B-cell conditions		5,046	1,796	1.00 (Ref)
B-cell conditions		53	50	2.90 (1.94–4.35)	–
No multiple organs		5,053	1,797	1.00 (Ref)
Multiple organs		64	46	2.24 (1.50–3.33)	–
None/any	T1	1,965	549	1.00 (Ref)
	T2	1,717	578	1.24 (1.08–1.43)
	T3	1,575	787	1.81 (1.59–2.07)	–
None	T1	1,888	513	1.00 (Ref)
	T2	1,656	550	1.25 (1.09–1.44)
	T3	1,520	745	1.82 (1.59–2.08)
Any	T1	77	36	1.52 (0.99–2.33)
	T2	61	28	1.73 (1.07–2.79)	P interaction
	T3	55	42	2.65 (1.71–4.10)	= 0.82
No B-cell conditions	T1	1,881	512	1.00 (Ref)
	T2	1,647	545	1.24 (1.08–1.43)
	T3	1,518	739	1.80 (1.57–2.07)
B-cell conditions	T1	22	18	2.94 (1.52–5.70)
	T2	18	14	3.27 (1.56–6.84)	P interaction
	T3	13	18	6.46 (3.04–13.7)	= 0.49
No multiple organs	T1	1,885	512	1.00 (ref)
	T2	1,650	544	1.24 (1.08–1.43)
	T3	1,518	741	1.81 (1.58–2.07)
Multiple organs	T1	31	17	2.18 (1.16–4.11)
	T2	19	12	2.54 (1.17–5.48)	P interaction
	T3	14	17	5.92 (2.80–12.5)	= 0.34

Note: See Supplementary Table S3 for definition of autoimmune condition categories.

^aWald test for homogeneity.